Drug intelligence / Profile preview

AZD0947

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD0947 (also known as ZD-0947) is a small molecule dual-action potassium channel modulator that acts as an activator of ATP-sensitive potassium (KATP) channels and an agonist of the voltage-gated potassium channel subunit Kv7.2 (KCNQ2). Developed by AstraZeneca, the compound was primarily investigated for the treatment of overactive bladder (OAB). By activating these potassium channels, AZD0947 aims to hyperpolarize smooth muscle cells in the bladder, thereby reducing detrusor overactivity and increasing bladder capacity. Despite its novel mechanism, the development of AZD0947 has been discontinued.

Targets

KATP channel (ATP-sensitive potassium channel)KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)

Beyond the preview

Go deeper on AZD0947.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD0947.

Explore the full profile